Maintenance
Tirzepatide Maintenance Phase
Maintenance is the phase after weight loss slows, when the goal shifts from further reduction to holding the result. Evidence from SURMOUNT-4 shows continued treatment maintains weight loss while withdrawal produces regain. Whether a reduced dose can maintain results is the question SURMOUNT-MAINTAIN was designed to answer, and its data is not yet verified here.
Key takeaways
- Maintenance means holding a result, not continuing to lose.
- SURMOUNT-4 showed continued treatment maintains loss; stopping does not.
- Whether a reduced dose maintains results is still under study.
- Reduced-dose maintenance is a supervised clinical strategy, not consumer microdosing.
- Maintenance dose decisions belong to a prescriber and are not published here.
| Goal of the phase | Holding weight loss rather than continuing to reduce |
|---|---|
| Supporting evidence | SURMOUNT-4 (continuation maintained loss) |
| Reduced-dose question | SURMOUNT-MAINTAIN — not yet verified here |
| Individual dosing guidance | Not published on this site |
| Common misconception | That maintenance means stopping |
What actually changes during maintenance?
The clinical target changes rather than the treatment. Weight loss naturally decelerates as energy requirements fall with reduced body mass, and at some point the curve flattens. That flattening is the expected end of the reduction phase, not treatment failure.
The decision at that point is whether to continue at the same dose, adjust it, or stop — and only the first two have supporting evidence for holding the result.
Is reduced-dose maintenance the same as microdosing?
No, and the distinction matters commercially. Reduced-dose maintenance means a prescriber lowers a dose that has already produced a result, with monitoring, once a target is reached. Commercial microdosing means starting below the studied range hoping for proportional benefit at lower cost.
The first is a supervised strategy under formal study. The second has no randomised evidence at all and is primarily a pricing proposition.
What the evidence shows
- Continued treatment maintains weight loss in randomised withdrawal evidence.
What the evidence does not show
- That a specific reduced dose maintains results — that data is not verified here.
- That maintenance can be self-managed without prescriber involvement.
Related: SURMOUNT-MAINTAIN · Long-term use
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Continued and reduced-dose evidence and monitoring and cost, organised around the primary question of tirzepatide maintenance dose. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Continued and reduced-dose evidence | Covered on this page | Primary evidence |
| Monitoring and cost | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on tirzepatide maintenance dose.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
What is the maintenance phase?
The period after weight loss slows, when the goal is holding the result rather than reducing further.
Can I lower my dose to maintain?
That is a prescriber decision. The trial designed to answer it has not been verified on this site.
Is stopping an option during maintenance?
SURMOUNT-4 showed substantial regain after stopping. It remains an individual clinical decision.
Is maintenance dosing the same as microdosing?
No. Maintenance lowers an already-effective dose under supervision; microdosing starts below the studied range without randomised evidence.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.